Job Trends
Labor Market Reports
BioSpace’s 2026 U.S. Life Sciences Employment Outlook examines the state of the biopharma workforce amid ongoing funding pressure, elevated layoffs and cautious hiring sentiment, while highlighting early signals of stabilization and cautious optimism for the year ahead.
BioSpace’s 2025 Q4 U.S. Life Sciences Job Market update highlights early signs of stabilization in biopharma hiring, with modest gains in job postings, slowing layoffs, and cautiously improving sentiment heading into 2026.
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
Now Hiring
Looking for an IT job? From data engineer to information security, check out the BioSpace list of 10 companies hiring life sciences professionals like you.
More biopharma organizations were actively recruiting at the end of 2025 than 2024, based on the new BioSpace employment outlook report. Areas in demand this year include research and development and clinical. Organizations are also prioritizing artificial intelligence hires.
Looking for a research and development job? Check out the BioSpace list of 12 companies hiring life sciences professionals like you.
Career Advice
If workloads aren’t adjusted as needed, the company’s priorities are already compromised. Executive coach Angela Justice explores what happens when goals move forward without removing unnecessary work and what to do about it.
THE LATEST
According to the second biennial 2019 Life Sciences Ideal Employer Report by BioSpace, the top three most important attributes cited by life sciences professionals around the world are the opportunity to do interesting and meaningful work, a competitive salary and health benefits.
Last week was an unusually busy week for clinical trial news, with numerous companies presenting results at conferences. Here’s a look at the top stories.
AveXis presented new interim data from the Phase III SPR1NT trial of Zolgensma (onasemnogene abeparvovec-xioi) in spinal muscular atrophy (SMA) Type 1.
Nation’s largest public health plan with nearly 2.2 million members taps Ntooitive to drive brand awareness, leveraging agency’s new marketing solution called Ntooitive Healthcare
Pulmotect, Inc., a clinical-stage biotechnology company developing an inhaled immunomodulatory agent, is pleased to announce the appointment of Dr. Kumar Srinivasan to its Board of Directors.
A University of Houston chemist is exploring the link between copper protein molecules in brain cells and their link to neurodegenerative diseases like Alzheimer’s.
Clinical Utility Study will Evaluate the Prolaris® Test in Men with Prostate Cancer
The biopharma company will utilize Coursera’s enterprise platform, Coursera for Business, to offer educational programs to its 108,000 staffers around the world.
The company presented the data at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
Improving Outcomes for Prostate Cancer Patients